Ophthalmic Business News

VVN539 ophthalmic solution met its primary endpoints for the treatment of primary open-angle glaucoma or ocular hypertension in a phase 2 study, according to a press release from VivaVision Biotech.

Laura B. Enyedi, MD, Laura M. Periman, MD, and Dagny Zhu, MD, discuss bullying, harassment and discrimination in the workplace with Audrey Talley Rostov, MD.

Bausch + Lomb is making changes to its executive leadership team, including the elevation of all business unit heads, according to a press release.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Stephen McLeod, MD, about his new position and the future of the American Academy of Ophthalmology.

With the rapid rise of interest rates in the last year, many physicians might be interested and surprised to learn where extremely low rates still exist.

NEW ORLEANS— In this Healio Video Perspective from the ARVO meeting, Kaushal Solanki discusses the EyeArt AI eye screening system, which was cleared by the FDA for diabetic retinopathy detection in 2020.

Norlase secured $11 million in funding following the FDA clearance and CE mark approval of the Echo green pattern laser photocoagulator, according to a press release.

Jim Mazzo, executive chairman of Neurotech, received the Ellis Island Medal of Honor in a ceremony on the island, a memorable evening for the 4-decade industry executive of the ophthalmic industry.

OCS-01 eye drops met the primary and secondary endpoints for the treatment of diabetic macular edema in stage 1 of the phase 3 DIAMOND trial, according to a press release from Oculis.

Tanfanercept did not demonstrate statistical significance in improvement in central corneal staining score or eye dryness score at week 8, the primary outcome measures of the phase 3 VELOS-3 trial, according to HanAll Biopharma.